Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 4, 2022

Primary Completion Date

January 29, 2026

Study Completion Date

January 29, 2026

Conditions

Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia-1Chronic Myelomonocytic Leukemia-2Myelodysplastic/Myeloproliferative Neoplasm

Interventions

DRUG

Decitabine

Given IV

BIOLOGICAL

Tagraxofusp-erzs

Given IV

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER